1. Search Result
Search Result
Results for "

Adp Inhibitors

" in MedChemExpress (MCE) Product Catalog:

104

Inhibitors & Agonists

1

Fluorescent Dye

1

Peptides

14

Natural
Products

11

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N2522
    Carboxyatractyloside dipotassium
    1 Publications Verification

    Gummiferin dipotassium

    Others Others
    Carboxyatractyloside dipotassium is a toxic natural product, acts as an inhibitor of ADP/ATP carrier, inhibits mitochondrial ADP/ATP transport .
    Carboxyatractyloside dipotassium
  • HY-N1502
    Carboxyatractyloside tripotassium
    1 Publications Verification

    Gummiferin tripotassium

    Others Cancer
    Carboxyatractyloside (Gummiferin) tripotassium is a toxic natural product, acts as an inhibitor of ADP/ATP carrier, inhibits mitochondrial ADP/ATP transport from the inner mitochondria to the inner mitochondria. Carboxyatractyloside tripotassium can be used for the study of cellular energy metabolism and mitochondrial biology .
    Carboxyatractyloside tripotassium
  • HY-147245

    STP1002

    PARP Cancer
    Basroparib is a potent poly (ADP-ribose) polymerase (PARP) inhibitor, with antineoplastic activity .
    Basroparib
  • HY-134318B

    DNA/RNA Synthesis Others
    8-Azido-ADP (disodium) is a covalent-binding inhibitor of mitochondrial adenine nucleotide translocation. 8-Azido-ADP (disodium) causes irreversible inhibition of adenine nucleotide exchange in a light-dependent reaction. 8-Azido-ADP (disodium) inhibits the normal state 4 → 3 transitions of mitochondrial respiration induced by ADP . 8-Azido-ADP (disodium) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
    8-Azido-ADP disodium
  • HY-156623

    PARP Cancer
    Lerzeparib is an (ADP-ribose) polymerase (PARP) inhibitor, with antineoplastic activity .
    Lerzeparib
  • HY-107867

    Others Cardiovascular Disease
    Clopidogrel sulfate is an antiplatelet agent. Specifically, Clopidogrel sulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. Clopidogrel sulfate can be used for research of heart disease and stroke .
    (±)-Clopidogrel bisulfate
  • HY-B0153A

    Adenosine Receptor Cardiovascular Disease
    Ticlopidine hydrochloride is an adenosine diphosphate (ADP) receptor inhibitor against platelet aggregation with IC50 of ~2 μM.
    Ticlopidine hydrochloride
  • HY-135846

    Poly(ADP-ribose) Glycohydrolase (PARG) Cancer
    PDD00031705 is a benzimidazolone core cell-inactive inhibitor of Poly (ADP-ribose) glycohydrolase (PARG) .
    PDD00031705
  • HY-134216

    Endogenous Metabolite NO Synthase Cardiovascular Disease
    MAHMA NONOate is a NO donor. MAHMA NONOate effectively inhibits platelet aggregation induced by either collagen or ADP .
    MAHMA NONOate
  • HY-U00223

    PARP Cancer
    WD2000-012547 is a selective poly(ADP-ribose)-polymerase (PARP-1) inhibitor with a pKi of 8.221.
    WD2000-012547
  • HY-108360
    PDD 00017273
    5+ Cited Publications

    Poly(ADP-ribose) Glycohydrolase (PARG) Cancer
    PDD 00017273 is a potent inhibitor of Poly(ADP-ribose) Glycohydrolase (PARG), with an IC50 of 26 nM, and a KD of 1.45 nM .
    PDD 00017273
  • HY-G0023

    Niraparib carboxylic acid metabolite M1; M1 metabolite of niraparib

    Drug Metabolite Others
    Niraparib metabolite M1 is a metabolite of niraparib, and the latter one acts as a novel poly(ADP-Ribose) polymerase (PARP) inhibitor.
    Niraparib metabolite M1
  • HY-142657

    PARP Cancer
    PARP1-IN-7 is an inhibitor of poly(ADP-ribose) polymerase-1 (PARP1) as an anticancer agent.
    PARP1-IN-7
  • HY-101020

    2-Picolinamide

    PARP Metabolic Disease
    Picolinamide (2-Picolinamide) is an inhibitor of Poly(ADP-ribose) synthetase of nuclei from rat pancreatic islet cells .
    Picolinamide
  • HY-136501

    P2Y Receptor Cardiovascular Disease
    MRS2395, an dipivaloyl derivative, is a potent P2Y12 receptor antagonist. MRS2395 inhibits ADP-induced platelet activation with a Ki of 3.6 μM. MRS2395 inhibits cAMP induced by ADP in rat platelets in the presence of PGE1 with an IC50 of 7 µM. MRS2395 enhances platelet dense granule release in response to TRAP-6 .
    MRS2395
  • HY-Z0283S

    Benzenecarboxamide-15N; Phenylamide-15N

    Endogenous Metabolite PARP Others
    Benzamide- 15N is a 15N-labeled Benzamide. Benzamide inhibits poly(ADP-ribose) polymerase (PARP)[1][2].
    Benzamide-15N
  • HY-B0153AS

    Adenosine Receptor Cardiovascular Disease
    Ticlopidine-d4 (hydrochloride) is the deuterium labeled Ticlopidine hydrochloride. Ticlopidine hydrochloride is an adenosine diphosphate (ADP) receptor inhibitor against platelet aggregation with IC50 of ~2 μM.
    Ticlopidine-d4 hydrochloride
  • HY-115666

    Poly(ADP-ribose) Glycohydrolase (PARG) Cancer
    COH34 analog 1, a metabolite, is an oxidized analog of COH34. COH34 is a potent poly(ADP-ribose) glycohydrolase (PARG) inhibitor .
    COH34 analog 1
  • HY-133530

    Poly(ADP-ribose) Glycohydrolase (PARG) Others
    PDD00017238 is a potent inhibitor of Poly(ADP-ribose) Glycohydrolase (PARG), with EC50 values of 40 nM and 55 nM in biochemical assay and cell POM, respectively .
    PDD00017238
  • HY-D1107

    PARP Others
    NCT-TFP is PARP probe used to identifying Poly(ADP-ribose) polymerases (PARP) inhibitors (extracted from patent US20190331688A1) .
    NCT-TFP
  • HY-146248

    Poly(ADP-ribose) Glycohydrolase (PARG) Others
    TFMU-ADPr is a general substrate for monitoring poly(ADP-ribose) glycohydrolase (PARG) activity. TFMU-ADPr can directly report on total PAR hydrolase activity via release of a fluorophore. TFMU-ADPr has excellent reactivity, generality, stability, and usability. TFMU-ADPr is a versatile tool for assessing small-molecule inhibitors in vitro and probing the regulation of ADP-ribosyl catabolic enzymes .
    TFMU-ADPr
  • HY-U00422

    PARP Cancer
    K-756 is a direct and selective tankyrase (TNKS) inhibitor, which inhibits the ADP-ribosylation activity of TNKS1 and TNKS2 with IC50s of 31 and 36 nM, respectively.
    K-756
  • HY-15284

    PCR 4099

    P2Y Receptor Cardiovascular Disease
    Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .
    Prasugrel
  • HY-15284A

    PCR 4099 hydrochloride

    P2Y Receptor Cardiovascular Disease
    Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and proagent, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .
    Prasugrel hydrochloride
  • HY-16929
    Latrunculin A
    5+ Cited Publications

    LAT-A

    Arp2/3 Complex Cancer
    Latrunculin A (LAT-A), found in the red sea sponge Latrunculia magnifica, is a G-actin polymerization inhibitor. Latrunculin A binds to actin monomers and inhibits polymerization of actin with Kds of 0.1, 0.4, 4.7 μM and 0.19 μM for ATP-actin, ADP-Pi-actin, ADP-actin and G-actin, respectively. Latrunculin A has effective anti-metastatic properties for cancer research. Latrunculin A blocks cell migration .
    Latrunculin A
  • HY-146248A

    Poly(ADP-ribose) Glycohydrolase (PARG) Others
    TFMU-ADPr triethylamine is a general substrate for monitoring poly(ADP-ribose) glycohydrolase (PARG) activity. TFMU-ADPr triethylamine can directly report on total PAR hydrolase activity via release of a fluorophore. TFMU-ADPr triethylamine has excellent reactivity, generality, stability, and usability. TFMU-ADPr triethylamine is a versatile tool for assessing small-molecule inhibitors in vitro and probing the regulation of ADP-ribosyl catabolic enzymes .
    TFMU-ADPr triethylamine
  • HY-148710

    PARP Inflammation/Immunology
    ARTD10/PARP10-IN-2 (compound 19) is a potent and non-selective PARP inhibitor, targeting to mono-ADP-ribosyltransferases ARTD10/PARP10 and poly(ADP-ribose) polymerase-1 ARTD1/PARP1 with IC50s of 2.0 μM, and 9.7 μM, respectively .
    ARTD10/PARP10-IN-2
  • HY-123669

    P2Y Receptor Cardiovascular Disease
    R-138727, the thiol-containing active metabolite of Prasugrel, is an irreversible platelet P2Y12 receptor inhibitor. R-138727 inhibits ADP-induced platelet aggregation .
    R-138727
  • HY-133531

    Poly(ADP-ribose) Glycohydrolase (PARG) Others
    PDD00017272 (34f) is a potent inhibitor of Poly(ADP-ribose) Glycohydrolase (PARG), with EC50 of 4.8 nM and 9.2 nM in biochemical assay and cell POM, respectively .
    PDD00017272
  • HY-N7614

    Schidigerasaponin F2; Timosaponin AII

    Others Cardiovascular Disease
    Anemarrhenasaponin A2 (Schidigerasaponin F2) is a steroidal saponin isolated from the rhizomes of Anemarrhena asphodeloides. Anemarrhenasaponin A2 inhibits ADP-induced platelet aggregation .
    Anemarrhenasaponin A2
  • HY-15284B

    PCR 4099 (Maleic acid)

    P2Y Receptor Cardiovascular Disease
    Prasugrel (PCR 4099) Maleic acid is a thienopyridine and proagent, inhibits platelet function. Prasugrel Maleic acid is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .
    Prasugrel (Maleic acid)
  • HY-113432

    2PY

    Endogenous Metabolite PARP Metabolic Disease
    Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro .
    Nudifloramide
  • HY-153581

    Others Others
    ARTD3/PARP3-IN-1 is an unselective inhibitor of diphtheria toxin-like ADP-ribosyltransferase 3 (ARTD3)/PARP3 .
    ARTD3/PARP3-IN-1
  • HY-N1462
    Atractyloside potassium salt
    2 Publications Verification

    Chloride Channel Cardiovascular Disease
    Atractyloside potassium salt is a toxic diterpenoid glycoside that can be isolated from the fruits of Xanthium sibiricum. Atractyloside potassium salt is a powerful and specific inhibitor of mitochondrial ADP/ATP transport. Atractyloside potassium salt inhibits chloride channels from mitochondrial membranes of rat heart .
    Atractyloside potassium salt
  • HY-125989
    2-Methylthio-AMP
    1 Publications Verification

    2-MeSAMP; 2-Methylthioadenosine 5′-monophosphate; 2-Methylthioadenosine 5′-phosphate

    P2Y Receptor Cardiovascular Disease
    2-Methylthio-AMP (2-MeSAMP) is a selective and direct P2Y12 antagonist. 2-Methylthio-AMP is an inhibitor of ADP-dependent platelet aggregation .
    2-Methylthio-AMP
  • HY-18740A

    HL 725

    Phosphodiesterase (PDE) Metabolic Disease
    Trequinsin hydrochloride (HL 725) is an extremely potent inhibitor of platelet CAMP phosphodiesterase (PDE), with an IC50 of 0.25 nM. Trequinsin hydrochloride (HL 725) is an extremely potent inhibitor of the aggregation of human platelets induced in vitro by ADP, collagen, thrombin and epinephrine .
    Trequinsin hydrochloride
  • HY-125989B

    2-MeSAMP diTEA; 2-Methylthioadenosine 5′-monophosphate diTEA; 2-Methylthioadenosine 5′-phosphate diTEA

    P2Y Receptor Cardiovascular Disease
    2-Methylthio-AMP (2-MeSAMP) diTEA is a selective and direct P2Y12 antagonist. 2-Methylthio-AMP diTEA is an inhibitor of ADP-dependent platelet aggregation .
    2-Methylthio-AMP diTEA
  • HY-15284S1

    PCR 4099-d3

    P2Y Receptor Cardiovascular Disease
    Prasugrel-d3 is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[1].
    Prasugrel-d3
  • HY-15284S

    PCR 4099-d5

    Isotope-Labeled Compounds P2Y Receptor Cardiovascular Disease
    Prasugrel-d5 is deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[1].
    Prasugrel-d5
  • HY-B0889
    Ethacridine lactate monohydrate
    2 Publications Verification

    Acrinol monohydrate

    Bacterial Infection
    Ethacridine lactate (Acrinol) monohydrate is a widely used antiseptic and abortifacient. Ethacridine lactate monohydrate is effective against Staphylococcus aureus and other gram-positive cocci. Ethacridine lactate monohydrate is also a poly(ADP-ribose) glycohydrolase (PARG) inhibitor .
    Ethacridine lactate monohydrate
  • HY-B2174
    Ethacridine lactate
    2 Publications Verification

    Acrinol

    Bacterial Infection
    Ethacridine lactate (Acrinol) is a widely used antiseptic and abortifacient. Ethacridine lactate is effective against Staphylococcus aureus and other gram-positive cocci. Ethacridine lactate is also a poly(ADP-ribose) glycohydrolase (PARG) inhibitor .
    Ethacridine lactate
  • HY-N7765

    HCV Bacterial Apoptosis Fungal Infection Inflammation/Immunology Cancer
    Oenothein B is a dimeric macrocyclic ellagitannin and has widely pharmacological activities, including antioxidant, anti-inflammatory, antifungal, anti-HCV, and antitumor properties. Oenothein B is a potent and specific inhibitor of poly(ADP-ribose) glycohydrolase .
    Oenothein B
  • HY-W051513

    PARP Others
    2-Methylquinazolin-4-ol is a potent competitive poly(ADP-ribose) synthetase inhibitor, with a Ki of 1.1 μM. 2-Methylquinazolin-4-ol mammalian aspartate transcarbamylase (ATCase) inhibitor, with 0.20 mM .
    2-Methylquinazolin-4-ol
  • HY-113723

    P2Y Receptor Cardiovascular Disease
    MRS2298? is a potent acyclic P2Y1 receptor antagonist with a Ki of 29.6 nM. MRS2298 inhibits the ADP-induced aggregation of human platelets with an IC50 of 62.8 nM. MRS2298 inhibits Ca 2+ rise in platelets with an IC50 of 810 nM .
    MRS2298
  • HY-15284S2

    PCR 4099-d4

    P2Y Receptor Cardiovascular Disease
    Prasugrel-d4 is the deuterium labeled Prasugrel[1]. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[2].
    Prasugrel-d4
  • HY-136142

    Drug Metabolite Others
    Prasugrel chloride impurity is a catp impurity of Prasugrel, exacted from patent US20130345428A1, line 0053. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .
    Prasugrel chloride impurity
  • HY-148709

    PARP Inflammation/Immunology
    ARTD10/PARP10-IN-1 (compound 23) is a potent and non-selective PARP inhibitor, targeting to mono-ADP-ribosyltransferases ARTD7/PARP15, ARTD8/PARP14, ARTD10/PARP10 and poly(ADP-ribose) polymerase-1 (ARTD1/PARP1) with IC50s of 1.7 μM, 1.6 μM, 0.8 μM, and 4.4 μM, respectively .
    ARTD10/PARP10-IN-1
  • HY-N10272

    Fungal Bacterial Infection
    Avenaciolide is an antifungal bis-γ-lactone found in Aspergillus avenaceus. Avenaciolide has also antibacterial action. Avenaciolide is a specific inhibitor of glutamate transport in rat liver mitochondria. Avenaciolide interferes with the ability of ADP to stimulate the rate of glutamate oxidation .
    Avenaciolide
  • HY-137924

    Poly(ADP-ribose) Glycohydrolase (PARG) Cancer
    JA2131 is a small molecular inhibitor of Poly(ADP-ribose) Glycohydrolase (PARG) (IC50=0.4 μM). JA2131 regulate DNA damage responses, causes replication fork stalling and cancer cell death .
    JA2131
  • HY-119860

    ONO 41483

    Others Cardiovascular Disease
    Ataprost (ONO 41483) is an orally active Carboprostacyclin (HY-112322) analogue. Ataprost exhibits 2.6 times more active than Carboprostacyclin in inhibiting ADP-induced platelet aggregation in vitro. Ataprost has the ability to relieve coronary spasm .
    Ataprost
  • HY-141867

    Z-Phe-Phe-FMK

    Cathepsin Neurological Disease
    Z-FF-FMK is a selective cathepsin-L inhibitor. Z-FF-FMK can prevent β-amyloid to induce apoptotic changes such as activation of caspase-3, cleavage of the DNA repair enzyme, poly-ADP ribose polymerase, and DNA fragmentation .
    Z-FF-FMK
  • HY-12762
    QS11
    1 Publications Verification

    Others Cancer
    QS11 is an inhibitor of ARFGAP1 (ADP-ribosylation factor GTPase-activating protein 1), with an EC50 of 1.5 µM. QS11 modulates Wnt/β-catenin signaling through an effect on protein trafficking. QS11 inhibits migration of ARFGAP overexpressing breast cancer cells .
    QS11
  • HY-U00235

    Integrin Inflammation/Immunology
    SR121566A is a novel non-peptide Glycoprotein IIb/IIIa (GP IIb-IIIa) antagonist, which can inhibit ADP-, arachidonic acid- and collagen-induced human platelet aggregation with IC50s of 46±7.5, 56±6 and 42±3 nM, respectively.
    SR121566A
  • HY-113371

    Methylcitric acid

    Endogenous Metabolite Metabolic Disease
    2-Methylcitric acid (Methylcitric acid) is an endogenous metabolite in the 2-methylcitric acid cycle. 2-Methylcitric acid accumulates in methylmalonic and propionic acidemias and acts as a marker metabolite. 2-Methylcitric acid markedly inhibits ADP-stimulated and uncoupled respiration in mitochondria supported by glutamate .
    2-Methylcitric acid
  • HY-108657

    P2Y Receptor Neurological Disease
    MRS2279 is a selective and high affinity P2Y1 receptor antagonist, with a Ki of 2.5 nM and an IC50 of 51.6 nM. MRS2279 competitively inhibits ADP-promoted platelet aggregation with an apparent affnity (pKB=8.05) .
    MRS2279
  • HY-150207

    PARP Inflammation/Immunology
    RBN-3143 is a potent and NAD+-competitive catalytic PARP14 inhibitor with an IC50 value of 4 nM. RBN-3143 inhibits PARP14-mediated ADP-ribosylation and stabilizes PARP14 in cell lines. RBN-3143 can be used in research of lung inflammation .
    RBN-3143
  • HY-100540
    Golgicide A
    3 Publications Verification

    GCA

    Enterovirus Infection Cancer
    Golgicide A (GCA) is a potent, highly specific, and reversible inhibitor of the cis-Golgi ADP-ribosylation factor guanine nucleotide exchange factors (ArfGEF) GBF1 . Golgicide A drastically reduced replication of coxsackievirus B3 (CVB3) and other human enterovirus species .
    Golgicide A
  • HY-W010791

    Endogenous Metabolite Others
    Adenosine 5'-diphosphate (ADP) sodium salt is a nucleoside diphosphate, which is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate sodium salt induces human platelet aggregation and inhibits stimulated adenylate cyclase by an action at P2T-purinoceptors .
    Adenosine 5'-diphosphate sodium salt
  • HY-128760
    COH34
    1 Publications Verification

    Poly(ADP-ribose) Glycohydrolase (PARG) Cancer
    COH34 is a potent and specific poly(ADP-ribose) glycohydrolase (PARG) inhibitor with an IC50 of 0.37 nM. COH34 binds to the catalytic domain of PARG (Kd=0.547 μM), thereby prolonging PARylation at DNA lesions and trapping DNA repair factors .
    COH34
  • HY-146248B

    Others Metabolic Disease
    TFMU-ADPr is a universal substrate for monitoring PARG activity. TFMU-ADPr directly reports the total bar number hydrolase activity by releasing fluorophore. TFMU-ADPr is a general tool for evaluating small molecule inhibitors and exploring the regulation of ADP-ribose catabolic enzymes in vitro .
    TFMU-ADPr diammonium
  • HY-112433A

    Others Inflammation/Immunology
    (S)-NIK SMI1 is the inactive isomer of NIK SMI1 (HY-112433), and can be used as an experimental control. NIK SMI1 is a potent, selective NF-κB inducing kinase (NIK) inhibitor, which inhibits NIK-catalyzed hydrolysis of ATP to ADP with IC50 of 0.23±0.17 nM.
    (S)-NIK SMI1
  • HY-108657A
    MRS2279 diammonium
    1 Publications Verification

    P2Y Receptor Neurological Disease
    MRS2279 diammonium is a selective and high affinity P2Y1 receptor antagonist, with a Ki value of 2.5 nM and an IC50 value of 51.6 nM. MRS2279 diammonium competitively inhibits ADP-promoted platelet aggregation with an pKb value of 8.05 .
    MRS2279 diammonium
  • HY-127111
    NDI-091143
    2 Publications Verification

    ATP Citrate Lyase Cancer
    NDI-091143 is a potent and high-affinity human ATP-citrate lyase (ACLY) inhibitor with an IC50 of 2.1 nM (ADP-Glo assay), a Ki of 7.0 nM and a Kd of 2.2 nM. NDI-091143 inhibits ACLY catalysis allosterically, by stabilizing large conformational changes in the citrate domain that indirectly block the binding and recognition of citrate .
    NDI-091143
  • HY-W009276

    Methyl GLA

    Apoptosis Cancer
    γ-Linolenic Acid methyl ester (Methyl GLA) is an esterified version of γ-Linolenic Acid (GLA), which is an ω-6 fatty acid, serves as melanoma cell proliferation inhibitors. γ-Linolenic Acid methyl ester inhibits ADP-induced blood platelet aggregation and induces apoptosis .
    γ-Linolenic Acid methyl ester
  • HY-152949

    Myosin Neurological Disease
    Myosin V-IN-1 (compound 8) is a potent and selective Myosin V inhibitor, with a Ki of 6 μM. Myosin V-IN-1 shows acute inhibition of myosin V. Myosin V-IN-1 slows the actin-activated myosin V ATPase by specifically inhibiting ADP release from the actomyosin complex .
    Myosin V-IN-1
  • HY-113371A

    Methylcitric acid trisodium

    Endogenous Metabolite Metabolic Disease
    2-Methylcitric acid trisodium (Methylcitric acid trisodium) is an endogenous metabolite in the 2-methylcitric acid cycle. 2-Methylcitric acid trisodium accumulates in methylmalonic and propionic acidemias and acts as a marker metabolite. 2-Methylcitric acid trisodium markedly inhibits ADP-stimulated and uncoupled respiration in mitochondria supported by glutamate .
    2-Methylcitric acid trisodium
  • HY-121497

    3-MBA

    PARP Bacterial Cancer
    3-Methoxybenzamide (3-MBA), an inhibitor of ADP-ribosyltransferase (ADPRTs) and PARP, inhibits cell division in Bacillus subtilis, leading to filamentation and eventually lysis of cells . 3-Methoxybenzamide (3-MBA) enhances in vitro plant growth, microtuberization, and transformation efficiency of blue potato (Solanum tuberosum L. subsp. andigenum) .
    3-Methoxybenzamide
  • HY-113432S

    Endogenous Metabolite PARP Metabolic Disease
    Nudifloramide-d3 (2PY-d3) is the deuterium labeled Nudifloramide. Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro[1].
    Nudifloramide-d3
  • HY-18901

    RIP kinase Inflammation/Immunology
    RIPK1-IN-4 (compound 8) is a potent and selective type II kinase inhibitor of receptor interacting protein 1 (RIP1) kinase and binds to a DLG-out inactive form of RIP1 with an IC50s of 16 nM and 10 nM for RIP1 and ADP-Glo kinase .
    RIPK1-IN-4
  • HY-112433
    NIK SMI1
    5+ Cited Publications

    NF-κB Inflammation/Immunology
    NIK SMI1 is a potent, selective NF-κB inducing kinase (NIK) inhibitor, which inhibits NIK-catalyzed hydrolysis of ATP to ADP with IC50 of 0.23±0.17 nM. NIK SMI1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    NIK SMI1
  • HY-129522

    CZ-48

    Toll-like Receptor (TLR) Neurological Disease
    Sulfo-ara-F-NMN (CZ-48) is a mimetic of nicotinamide mononucleotide (NMN). Sulfo-ara-F-NMN acts selectively, activating SARM1 but inhibiting CD38 (IC50 around 10 μM). Sulfo-ara-F-NMN induces intracellular cyclic ADP-ribose (cADPR) production .
    Sulfo-ara-F-NMN
  • HY-15045
    INO-1001
    1 Publications Verification

    PARP Cancer
    INO-1001 is a potent and selective poly (ADP-ribose) polymerase (PARP) inhibitor. INO-1001 is a potent enhancer of radiation sensitivity and enhances radiation-induced cell killing by interfering with DNA repair mechanisms, resulting in necrotic cell death . INO-1001 has anti-tumor effects .
    INO-1001
  • HY-108658

    P2Y Receptor Cardiovascular Disease
    MRS2500 tetraammonium is a potent, selective and stable antagonist of the P2Y1 receptor (Ki=0.78 nM for recombinant human P2Y1 receptor). MRS2500 tetraammonium inhibits the ADP-induced aggregation of human platelets with an IC50 value of 0.95 nM. Antithrombotic activity .
    MRS2500 tetraammonium
  • HY-105692

    PARP Neurological Disease
    DR2313 is a potent, selective, competitive and brain-penetrant inhibitor of poly(ADP-ribose) polymerase (PARP), with IC50s of 0.20 μM and 0.24 μM for PARP-1 and PARP-2, respectively. DR2313 exhibits neuroprotective effects on ischemic injuries in vitro and in vivo .
    DR2313
  • HY-100540A

    (Rac)-GCA

    Enterovirus Infection
    (Rac)-Golgicide A ((Rac)-GCA) is a racemate of Golgicide A. Golgicide A (GCA) is a potent, highly specific, and reversible inhibitor of the cis-Golgi ADP-ribosylation factor guanine nucleotide exchange factors (ArfGEF) GBF1 .Golgicide A drastically reduced replication of coxsackievirus B3 (CVB3) and other human enterovirus species .
    (Rac)-Golgicide A
  • HY-155348

    PARP Cancer
    Ru3 is a poly(ADP-ribose) polymerase 1 inhibitor. Ru3 induces apoptosisin MCF-7 cells by multiple modes, inclusive of inducing DNA damage, suppressing DNA damage repair, disturbing cell cycle distribution, decreasing the mitochondrial membrane potential, and increasing the intracellular reactive oxygen species levels .
    Ru3
  • HY-111557
    YM-254890
    5 Publications Verification

    P2Y Receptor Cardiovascular Disease
    YM-254890 is a selective Gαq/11 protein inhibitor isolated from Chromobacterium sp. YM-254890 shows no inhibition of other G protein subtypes. YM-254890 inhibits platelet aggregation induced by ADP by blocking the P2Y1 signal transduction pathway, with an IC50 value below 0.6 μM .
    YM-254890
  • HY-137742

    ULK Autophagy Cancer
    SBP-7455 is a potent, high affinity and orally active dual ULK1/ULK2 autophagy inhibitor with IC50s of 13 nM and 476 nM in the ADP-Glo assays, respectively. SBP-7455 potently inhibits ULK1/2 enzymatic activity and can be used for triple-negative breast cancer (TNBC) research .
    SBP-7455
  • HY-148754

    PARP Cancer
    PARP10-IN-3 is a selective mono‐ADP‐ribosyltransferase PARP10 inhibitor with an IC50 of 480 nM for human PARP10. PARP10-IN-3 reveals potent inhibition on PARP2 and PARP15 with IC50s of 1.7 μM for human PARP2 and human PARP15, respectively .
    PARP10-IN-3
  • HY-Z0283

    Benzenecarboxamide; Phenylamide

    Endogenous Metabolite PARP Others
    Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .
    Benzamide
  • HY-10885

    ABT-472

    PARP Cancer
    A-620223 succinate (ABT-472) is an orally available poly(ADP-ribose) polymerase (PARP) inhibitor. A-620223 succinate (ABT-472) exhibits very good potency against the PARP-1 enzyme with a Ki value of 8 nM and an EC50 value of 3 nM in whole cell assay, making it useful in cancer research .
    A-620223 succinate
  • HY-B0097
    Floxuridine
    3 Publications Verification

    5-Fluorouracil 2'-deoxyriboside

    Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Bacterial CMV HSV Apoptosis Infection Cancer
    Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis . Floxuridine has antiviral effects against HSV and CMV .
    Floxuridine
  • HY-152696

    Nucleoside Antimetabolite/Analog Others
    6-O-Methylinosine is a hypoxanthine analogue. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .
    6-O-Methylinosine
  • HY-113371S

    Methylcitric acid-d3

    Endogenous Metabolite Metabolic Disease
    2-Methylcitric acid-d3 is the deuterium labeled 2-Methylcitric acid. 2-Methylcitric acid (Methylcitric acid) is an endogenous metabolite in the 2-methylcitric acid cycle. 2-Methylcitric acid accumulates in methylmalonic and propionic acidemias and acts as a marker metabolite. 2-Methylcitric acid markedly inhibits ADP-stimulated and uncoupled respiration in mitochondria supported by glutamate[1].
    2-Methylcitric acid-d3
  • HY-N5021

    AHSYB

    Others Neurological Disease
    Anhydrosafflor yellow B (AHSYB) is a quinochalcone C-glycoside isolated from Carthamus tinctorius. Anhydrosafflor yellow B inhibits ADP-induced platelet aggregation, exhibits significant anti-oxidative effects in vitro, and possesses certain activity against H2O2-induced cytotoxicity in cultured PC12 cells and primary neuronal cells .
    Anhydrosafflor yellow B
  • HY-148753

    PARP Cancer
    PARP10-IN-2 is a potent mono‐ADP‐ribosyltransferase PARP10 inhibitor with an IC50 of 3.64 μM for human PARP10. PARP10-IN-2 reveals potent inhibition on PARP2 and PARP15 with IC50s of 27 μM and 11 μM for human PARP2 and human PARP15, respectively .
    PARP10-IN-2
  • HY-155807

    STAT JAK Apoptosis Cancer
    DPP is a Platinum(IV) complex, bearing pterostilbene-derived axial ligand. DPP inhibit the JAK2-STAT3 pathway in breast cancer (BC) cells with antiproliferative activity, and activates caspase-3 and cleaved poly ADP-ribose polymerase to induces apoptosis. DPP promotes the maturation and antigen presentation of dendritic cells, and exhibits in vivo safety .
    DPP
  • HY-17459
    Clopidogrel hydrogen sulfate
    Maximum Cited Publications
    15 Publications Verification

    (S)-(+)-Clopidogrel bisulfate; (S)-(+)-Clopidogrel hydrogen sulfate

    Cytochrome P450 P2Y Receptor Cardiovascular Disease Cancer
    Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation .Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .
    Clopidogrel hydrogen sulfate
  • HY-78263

    NSC 170724; 5-(2-Nitrovinyl)benzodioxole

    Src Syk Cancer
    MNS (NSC 170724), the beta-nitrostyrene derivative, is a potent tyrosine kinase inhibitor and a broad-spectrum antiplatelet agent. MNS completely inhibits U46619, ADP-, arachidonic acid-, collagen-, and thrombin-induced platelet aggregation with IC50 values of 2.1, 4.1, 5.8, 7.0, and 12.7 μM, respectively. MNS inhibits Src, Syk, and FAK with IC50 of 27.3, 2.8, and 97.6 μM, respectively .
    MNS
  • HY-W039271

    2-Chloro-6-O-methyl-inosine

    Nucleoside Antimetabolite/Analog Cancer
    2-Chloro-6-methoxypurine riboside is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .
    2-Chloro-6-methoxypurine riboside
  • HY-154017

    Nucleoside Antimetabolite/Analog Cancer
    2′-C-Methyl-6-O-methylinosine is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .
    2′-C-Methyl-6-O-methylinosine
  • HY-125209

    Others Cancer
    TH5427 is a promising, targeted inhibitor that can be used to further study NUDT5 activity and ADP-ribose metabolism. TH5427, blocks progestin-dependent, PAR-derived nuclear ATP synthesis and subsequent chromatin remodeling, gene regulation and proliferation in breast cancer cells. NUDT5 is recently identified as a rheostat of hormone-dependent gene regulation and proliferation in breast cancer cells .
    TH5427
  • HY-154393

    Nucleoside Antimetabolite/Analog Cancer
    2-Chloro-2'-deoxy-6-O-methylinosine is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .
    2-Chloro-2'-deoxy-6-O-methylinosine
  • HY-152678

    Nucleoside Antimetabolite/Analog Cancer
    6-Methoxypurine-9-β-D-5’(R)-C-methylriboside is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .
    6-Methoxypurine-9-β-D-5’(R)-C-methylriboside
  • HY-W141392

    Nucleoside Antimetabolite/Analog Cancer
    2'-Fluoro-5'-O-DMT-2'-deoxyinosine-3'-CE-phosphoramidite is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .
    2'-Fluoro-5'-O-DMT-2'-deoxyinosine-3'-CE-phosphoramidite
  • HY-W392836

    Nucleoside Antimetabolite/Analog Cancer
    2'-O-Methyl-5'-O-dmt-inosine-3'-CE-phosphoramidite is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .
    2'-O-Methyl-5'-O-dmt-inosine-3'-CE-phosphoramidite
  • HY-17459S

    (S)-(+)-Clopidogrel bisulfate-d3; (S)-(+)-Clopidogrel-d3 hydrogen sulfate

    P2Y Receptor Cytochrome P450
    Clopidogrel-d3 (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate[1]. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation.Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[2][3][4][5][6].
    Clopidogrel-d3 hydrogen sulfate
  • HY-139039

    PROTACs CDK Cancer
    BSJ-4-116 is a PROTAC connected by ligands for Cereblon and CDK. BSJ-4-116 is a highly potent and selective CDK12 degrader (PROTAC) with an IC50 of 6 nM. BSJ-4-116 downregulates DDR genes through a premature termination of transcription, primarily through increasing poly(adenylation). BSJ-4-116 exhibits potent antiproliferative effects, alone and in combination with the poly(ADP-ribose) polymerase inhibitor Olaparib (HY-10162) .
    BSJ-4-116
  • HY-150062

    SARS-CoV Infection
    SARS-CoV-2 nsp3-IN-1 (Compound 15c) is a Mac1 (SARS-CoV-2 nsp3 macrodomain) inhibitor with the IC50 value of 6.1 μM. SARS-CoV-2 nsp3-IN-1 can inhibit Mac1 ADP-ribosylhydrolase activity. SARS-CoV-2 nsp3-IN-1 demonstrates notable selectivity for coronavirus macrodomains, especially towards SARS-CoV-2 Mac1 .
    SARS-CoV-2 nsp3-IN-1
  • HY-W010918S

    Adenosine diphosphate-d13 dilithium; Adp--d13 dilithium

    Isotope-Labeled Compounds Endogenous Metabolite Others
    Adenosine 5'-diphosphate-d13 (Adenosine diphosphate-d13 dilithium; ADP-d13) dilithium is deuterium labeled Adenosine 5'-diphosphate (HY-W010918). Adenosine 5'-diphosphate (Adenosine diphosphate) is a nucleoside diphosphate. Adenosine 5'-diphosphate is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate induces human platelet aggregation and inhibits stimulated adenylate cyclase by an action at P2T-purinoceptors.
    Adenosine 5'-diphosphate-d13 dilithium
  • HY-W010918S1

    Adenosine diphosphate-13C10 dilithium; Adp-13C10 dilithium

    Isotope-Labeled Compounds Endogenous Metabolite Others
    Adenosine 5'-diphosphate- 13C10 (Adenosine diphosphate- 13C10 dilithium; ADP- 13C10) dilithium is 13C-labeled Adenosine 5'-diphosphate (HY-W010918). Adenosine 5'-diphosphate (Adenosine diphosphate) is a nucleoside diphosphate. Adenosine 5'-diphosphate is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate induces human platelet aggregation and inhibits stimulated adenylate cyclase by an action at P2T-purinoceptors.
    Adenosine 5'-diphosphate-13C10 dilithium
  • HY-W010918S2

    Adenosine diphosphate-15N5 dilithium; Adp-15N5 dilithium

    Isotope-Labeled Compounds Endogenous Metabolite Others
    Adenosine 5'-diphosphate- 15N5 (Adenosine diphosphate- 15N5 dilithium; ADP- 15N5) dilithium is 15N labeled Adenosine 5'-diphosphate (HY-W010918). Adenosine 5'-diphosphate (Adenosine diphosphate) is a nucleoside diphosphate. Adenosine 5'-diphosphate is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate induces human platelet aggregation and inhibits stimulated adenylate cyclase by an action at P2T-purinoceptors.
    Adenosine 5'-diphosphate-15N5 dilithium
  • HY-122026

    PF-367

    GSK-3 Neurological Disease
    PF-04802367 (PF-367) is a highly selective GSK-3 inhibitor with an IC50 of 2.1 nM based on a recombinant human GSK-3β enzyme assay and 1.1 nM based on ADP-Glo assay. PF-04802367 shows desirable central nervous system (CNS) properties and potency. PF-04802367 is equally effective at inhibition of the two known GSK-3 isoforms (GSK-3α and GSK-3β) with IC50 values of 10.0 and 9.0 nM in mobility shift assays, respectively .
    PF-04802367
  • HY-149454

    P2Y Receptor Cancer
    P2Y1/P2Y12 antagonist-1 (compound 24w) is an orally available dual inhibitor of P2Y1 and P2Y12 with antiplatelet activity. P2Y1/P2Y12 antagonist-1 inhibits ADP-induced platelet aggregation in rabbit plasma with an IC50 of 4.23 μM. P2Y1/P2Y12 antagonist-1 exhibits potent inhibitory effects in rat thrombosis model.
    P2Y1/P2Y12 antagonist-1